MRMD · Marimed Inc. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $163.82M | $159.83M | $157.71M | $148.6M | $134.01M | $121.46M | $50.9M | $45.6M | $11.85M | $6.07M | $3.56M | $1.27M | $88.38K | $904 | $785 | |
| $56.31K | — | — | — | — | — | — | — | — | — | $56.5K | $56.15K | — | — | — | |
| $1M | — | $1.1M | $1.5M | $3.53M | $6.55M | $13.9M | $9.5M | $5.4M | — | — | — | — | — | — | |
| $105.45M | $101.95M | $95.1M | $82.68M | $70.05M | $55.2M | $19.57M | $26.9M | $4.04M | $2.19M | $1.35M | $1.57M | $190.17K | $26.29K | $19.95K | |
| $58.37M | $57.88M | $62.61M | $65.92M | $63.96M | $66.26M | $31.32M | $18.7M | $7.81M | $3.88M | $1.95M | -$296.65K | -$101.78K | -$25.38K | -$19.16K | |
| — | 36.22% | 39.7% | 44.36% | 47.73% | 54.55% | 61.55% | 41.01% | 65.9% | 63.86% | 54.62% | -23.35% | -115.16% | -2807.63% | -2441.15% | |
| — | — | — | — | — | — | — | — | — | — | — | $93.11K | — | — | — | |
| $27.3M | $26.14M | $25.62M | $22.13M | $20.74M | $27.56M | $9.9M | $8.82M | $10.05M | $2.88M | $651.06K | — | — | — | — | |
| $960.64K | — | — | — | — | — | — | — | — | — | $770.46K | $567.94K | $302.27K | $122.06K | $184.43K | |
| $3.01M | $3.4M | $2.95M | $3.03M | $1.28M | $690K | $390.48K | $197.5K | — | — | — | $366.67K | $20K | — | — | |
| $8.67M | $8.11M | $7.91M | $5.55M | $3.43M | — | $1.8M | $1M | $658K | $363K | $265.75K | — | — | — | — | |
| $60.75M | $60.7M | $60M | $51.53M | $43.59M | $39.4M | $16.79M | $60.23M | $13.17M | $3.75M | $1.17M | $1.39M | $715.57K | $532.76K | $755.62K | |
| -$2.38M | -$2.82M | $2.61M | $14.39M | $20.37M | $26.86M | $14.53M | -$41.53M | -$5.36M | $127.65K | $775.3K | -$1.69M | -$817.35K | -$558.15K | -$774.79K | |
| — | -1.76% | 1.65% | 9.68% | 15.2% | 22.12% | 28.55% | -91.07% | -45.19% | 2.1% | 21.75% | -133.1% | -924.77% | -61741.7% | -98698.98% | |
| $6.29M | $5.29M | $10.52M | $19.93M | $23.8M | — | $16.33M | -$40.53M | -$4.7M | $490.65K | $1.04M | — | — | — | — | |
| $7.96M | $7.5M | $6.94M | $9.19M | $1.69M | $2.36M | $9.81M | $12.72M | $4.37M | $592.42K | -$290.83K | -$206.56K | -$56.2K | — | — | |
| -$7.8M | -$8.04M | -$6.88M | -$20.98M | -$861K | -$3.05M | -$10.03M | -$40.28M | -$7.95M | $1.16M | $454.14K | — | — | — | — | |
| — | — | — | — | — | — | $98.81K | -$30.33M | -$43.22K | — | — | — | — | — | — | |
| — | $0 | -$145K | -$76K | -$1.08M | -$1.11M | -$349.64K | — | — | — | — | — | -$5404 | -$6684 | — | |
| -$10.18M | -$10.86M | -$4.27M | -$6.6M | $19.51M | $23.82M | $4.5M | -$81.81M | — | — | — | — | — | — | — | |
| $4.74M | $3.59M | $8.16M | $9.41M | $5.89M | $16.19M | $2.07M | $67.16K | — | — | — | — | — | — | — | |
| -$14.99M | -$14.48M | -$12.47M | -$16.03M | $13.47M | $7.23M | $2.14M | -$81.18M | -$13.6M | -$1.19M | -$198.85K | -$1.85M | -$7.42M | -$535.61K | -$809.54K | |
| — | -9.06% | -7.91% | -10.79% | 10.05% | 5.95% | 4.21% | -178.02% | -114.78% | -19.68% | -5.58% | -145.41% | -8396.65% | -59248.56% | -103126.11% | |
| $33K | $28K | $37K | $24K | $146K | $399K | $285.28K | -$696.21K | $295.4K | $165.02K | $520.02K | — | — | — | — | |
| USD/shares | -$0.05 | -$0.04 | -$0.03 | -$0.04 | $0.04 | $0.02 | $0.01 | -$0.39 | — | — | — | — | — | — | — |
| USD/shares | -$0.05 | -$0.04 | -$0.03 | -$0.04 | $0.04 | $0.02 | $0.01 | -$0.39 | — | — | — | — | — | — | — |
| shares | — | 390.14M | 379.15M | 363.4M | 337.7M | 326.47M | 266.98M | 208.72M | 192.38M | 116.28M | 52.02M | 31.98M | 31.9M | 30.33M | 19.81M |
| shares | — | 390.14M | 379.15M | 363.4M | 380.29M | 372.4M | 324.16M | 208.72M | 192.38M | 116.28M | 52.02M | — | — | — | — |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 41 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Product Sales | $89,024,000 | $91,275,000 | $95,517,000 | $92,836,000 | $82,127,000 | $28,980,763 | $1,542,037 |
| Product Sales Wholesale | $69,579,000 | $62,895,000 | $48,788,000 | $32,865,000 | $26,119,000 | $10,419,963 | — |
| Other | $1,223,000 | $3,539,000 | $4,293,000 | $8,309,000 | $13,218,000 | $1,183 | $48,588 |
| Product Sales from Related Party | — | — | — | — | — | — | $29,029,249 |
| Supply Procurement | — | — | — | $3,353,000 | $2,108,000 | $1,549,856 | $3,555,555 |
| License And Service | — | — | — | $582,000 | $1,483,000 | $1,684,792 | $1,794,161 |
| Management Service | — | — | — | $848,000 | $3,079,000 | $1,481,897 | $2,798,738 |
| Real Estate | — | — | — | — | $6,548,047 | $6,776,697 | $6,836,316 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$2,820,000 | $2,609,000 | $14,385,000 |